Roche Holding AG

Pharmaceutical manufacturers are rapidly shifting their obesity drug pipelines toward oral medications and infrequent dosing schedules to capture a larger share of the global weight-loss market. While Eli Lilly and …

Novo Nordisk‘s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker fights to regain investor confidence in its …

Zealand Pharma Outlines Ambitious 5-Year Obesity Drug Strategy Amidst Growing Competition Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for it’s anti-obesity portfolio …